熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化*

doi:10.3969/j.issn.1672-5069.2020.02.023

摘要/Abstract

摘要： 目的探讨应用熊去氧胆酸(UCDA)联合骨化三醇治疗原发性胆汁性肝硬化(PBC)患者的疗效及其对外周血T淋巴细胞亚群的影响。方法 2015年6月～2018年6月我院消化内科治疗的100例PBC患者,被随机分为观察组和对照组,每组50例。给予对照组UDCA治疗,给予观察组UDCA联合骨化三醇胶丸治疗,观察1年。结果在治疗1年末,观察组应答36例(72.0%),显著高于对照组的26例(52.0%,P<0.05);观察组血清ALP水平为(132.6±37.9)U/L,显著低于对照组【(151.6±47.1)U/L,P＜0.05】,GGT水平为(162.8±17.8) U/L,显著低于对照组【(189.7±18.0) U/L,P＜0.05】,TBA水平为(12.0±1.7)μmol/L,显著低于对照组【(16.2±2.1)μmol/L,P＜0.05 】;观察组血清25-(OH)2-D3为(19.0±4.5)ng/mL,显著高于对照组的【(11.2±3.8)ng/mL,P＜0.05】,CD4⁺细胞百分比为(3.4±1.1)%,显著高于对照组【(3.0±0.8)%,P＜0.05】,Th17细胞百分比为(1.5±0.8)%,显著低于对照组【(1.9±1.0)%,P＜0.05】;观察组和对照组血清DAO水平分别为(3.3±1.1)U/mL和(4.0±1.7)U/mL,D-乳酸水平分别为(2.1±1.6)mmol/L和(2.5±2.0)mmol/L,内毒素水平分别为(0.4±0.1)EU/mL和(0.6±0.2)EU/mL,均差异显著(P＜0.05)。结论应用UDCA联合骨化三醇胶丸能显著改善PBC患者肝功能指标,降低血清内毒素水平。

关键词: 原发性胆汁性肝硬化, 熊去氧胆酸, 骨化三醇, T淋巴细胞亚群, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of ursodeoxycholic acid (UDCA) combined with calcitriol in treatment of patients with primary biliary cirrhosis (PBC). Methods m 100 patients with PBC were randomly divided into observation and control group with 50 cases in each group. The patients in the control group was treated with UDCA, while those in the observation group was treated with UDCA combined with calcitriol capsules for one year. Result At the end of one year treatment, the response rate in the observation was 72.0%, much higher than 52.0% (P<0.05) in the control; serum ALP level was (132.6±37.9)U/L, significantly lower than 【(151.6±47.1)U/L, P＜0.05】, serum GGT level was (162.8±17.8) U/L, much lower than 【(189.7±18.0) U/L, P＜0.05】, serum TBA level was (12.0±1.7)μmol/L, significantly lower than 【(16.2±2.1)μmol/L, P＜0.05 】 in the control; serum 25-hydroxyvitamin D3 level was (19.0±4.5)ng/mL, significantly higher than 【(11.2±3.8)ng/mL, P＜0.05】, the percentage of peripheral blood CD4⁺ cells was (3.4±1.1)%, significantly higher than 【(3.0±0.8)%, P＜0.05】, that of Th17 cells was (1.5±0.8)%, much lower than 【(1.9±1.0)%, P＜0.05】 in the control; there were significant differences as respect to serum diamine oxidase [(3.3±1.1) U/mL vs. (4.0±1.7)U/mL], lactic acid [(2.1±1.6)mmol/L vs. (2.5±2.0)mmol/L] and endotoxin [(0.4±0.1)EU/mL vs. (0.6±0.2)EU/mL] levels in the two groups(all P＜0.05). Conclusion The application of UDCA and calcitriol combination might greatly improve liver functions in PBC patients.

Key words: Primary biliary cirrhosis, Ursodeoxycholic acid, Calcitriol, Tlymphocyte subsets, Therapy

贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.

Jia Jiao, Wang Fang, Zhang Bo, et al. Efficacy of ursodeoxycholic acid combined with calcitriol in treatment of patients with primary biliary cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(2): 240-243.

参考文献

[1] 孔祥璐, 郭晓霞. 中药联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化疗效系统评价. 实用肝脏病杂志, 2015, 18(4): 379-382.
[2] Guo J, Shi J, Wang H, et al. Emerging gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: a retrospective study. Exp Ther Med, 2019, 17(6): 4568-4576.
[3] 秦维, 陈宇萍, 杨昭, 等原发性胆汁性肝硬化患者肝组织转化生长因子β-1表达水平变化. 实用肝脏病杂志, 2018, 21(2): 237-240.
[4] 陶明玲, 张世斌, 吴燕京, 等. 原发性胆汁性肝硬化患者食管静脉曲张特点及其无创预测指标研究. 实用肝脏病杂志, 2017, 20(4): 439-442.
[5] Zhang J, Wen XY, Gao RP. Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report. World J Clin Cases, 2019, 7(10): 1206-1212.
[6] de Liso F, Matinato C, Ronchi M, et al. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature. Clin Chem Lab Med, 2017, 56(1): 25-31.
[7] Marzorati S, Lleo A, Carbone M, et al. The epigenetics of PBC: the link between genetic susceptibility and environment. Clin Res Hepatol Gastroenterol, 2016, 40(6): 650-659.
[8] Yang F, Yang Y, Wang Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther, 2017, 45(5): 733-743.
[9] Peng Y, Qi X, Guo X. Child-Pugh versus meld score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore), 2016, 95(8): e2877.
[10] Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the north american society for pediatric gastroenterology, hepatology, and nutrition and the european society for pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr, 2017, 64(1): 154-168.
[11] Voiosu AM, Wiese S, Voiosu TA, et al. Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. Eur J Gastroenterol Hepatol, 2018, 30(4): 392-397.
[12] Gulamhusein AF, Juran BD, Atkinson EJ, et al. Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up. Liver Int, 2016, 36(9): 1378-1382.
[13] Shimoda S, Tanaka A. It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology. Hepatol Res, 2016, 46(5): 407- 415.
[14] Van den B, Hindryckx P, Devisscher L, et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microbiol, 2017, 83(7): e02766-2776.
[15] Woodhouse CA, Patel VC, Singanayagam A, et al. The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther, 2018, 47(2): 192-202.
[16] Cusin F, Fernandes Azevedo L, Bonnaventure P, et al. Hepatocyte concentrations of indocyanine green reflect transfer rates across membrane transporters. Basic Clin Pharmacol Toxicol, 2017, 120(2): 171-178.
[17] Nakagawa R, Muroyama R, Saeki C, et al. Mir-425 regulates inflammatory cytokine production in CD4⁺ t cells via N-Ras upregulation in primary biliary cholangitis. J Hepatol, 2017, 66(6): 1223-1230.
[18] Dokmak S, Aussilhou B, Ragot E, et al. Reconstruction of bile duct injury and defect with the round ligament. J Gastrointest Surg, 2017, 21(9): 1540-1543.
[19] Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol, 2017, 11(9): 821-834.
[20] Halilbasic E, Steinacher D. Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases. Dig Dis, 2017, 35(3): 288-292.

熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*

Efficacy of ursodeoxycholic acid combined with calcitriol in treatment of patients with primary biliary cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	温博, 王炳元. Wilson’s病:一个潜在的可治疗的遗传性疾病^*[J]. 实用肝脏病杂志, 2020, 23(2): 156-158.
[2]	周翠梅, 胡立芬, 李家斌, 储雪琴, 郜玉峰. 思维导图在慢性乙型肝炎患者管理中应用价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 187-190.
[3]	张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*[J]. 实用肝脏病杂志, 2020, 23(2): 191-194.
[4]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[5]	王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.
[6]	张玉玲, 周瑾, 董宏伟. 超声点定量弹性成像技术对AIH和PBC患者肝纤维化诊断价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 231-235.
[7]	李永超, 任红军, 刘磊, 张松. 双重血浆吸附联合血浆置换治疗慢加急性乙型肝炎肝衰竭患者临床疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 236-239.
[8]	张惠勇, 吴秀欣, 徐成润. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 244-247.
[9]	范建高. 不忘初心,砥励前行[J]. 实用肝脏病杂志, 2020, 23(1): 1-1.
[10]	陈从新, 王莉苹. 应用皮质激素治疗肝衰竭存在什么争议？[J]. 实用肝脏病杂志, 2020, 23(1): 2-3.
[11]	范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握[J]. 实用肝脏病杂志, 2020, 23(1): 7-9.
[12]	纪宇欣, 李树臣. 应用糖皮质激素治疗肝衰竭临床疗效研究进展[J]. 实用肝脏病杂志, 2020, 23(1): 10-13.
[13]	李永华, 孙延芬, 王佳佳, 李艳颖, 于收. 恩替卡韦联合苦参素治疗慢性乙型肝炎患者疗效及其对外周血辅助性T淋巴细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 22-25.
[14]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[15]	孙红菊, 王衍颜, 徐丛聪, 赵红. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 54-57.